Comparative Pharmacology
Head-to-head clinical analysis: ASTEPRO versus ASTEPRO ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTEPRO versus ASTEPRO ALLERGY.
ASTEPRO vs ASTEPRO ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
Antihistamine; selectively antagonizes histamine H1 receptors, preventing histamine-mediated allergic responses.
One 0.15% ophthalmic solution drop instilled into the affected eye(s) twice daily (approximately every 8 to 12 hours).
One spray (205.5 mcg azelastine hydrochloride and 137 mcg fluticasone propionate) per nostril twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 28–36 hours. Clinical context: supports once-daily dosing; steady state reached after 5–7 days.
Terminal elimination half-life is 22-26 hours. Clinical context: supports once-daily dosing; steady state achieved within ~5 days.
Primarily renal elimination: approximately 70% of an oral dose is excreted unchanged in urine, with <10% as metabolites. Fecal elimination accounts for <20%.
Primarily renal excretion; approximately 70-80% of a dose is excreted as unchanged drug in urine, with the remainder as metabolites. Fecal elimination accounts for <10%.
Category C
Category C
Antihistamine (Nasal)
Antihistamine (Nasal)